Telum Therapeutics is a biotechnology company focused on developing engineered phage lytic proteins, known as enzybiotics, as alternatives to traditional antibiotics to combat multi-drug resistant bacterial infections. By creating a diverse collection of bacteriophages and lytic enzymes, the company aims to provide effective therapeutic options for patients suffering from serious infections caused by resistant pathogens.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ICFounders
Product
Problem
The increasing prevalence of multi-drug resistant bacteria poses a significant threat to global health, rendering traditional antibiotics ineffective for many serious infections. This necessitates the development of novel antimicrobial agents to combat resistant pathogens and improve patient outcomes.
Solution
Telum Therapeutics is developing engineered phage lytic proteins (EPLEs), also known as enzybiotics, as a new class of antimicrobial therapeutics to address multi-drug resistant bacterial infections. The company's APEXp® platform leverages synthetic biology and artificial intelligence to discover, engineer, and optimize EPLEs with enhanced potency, precision, and stability. These next-generation enzybiotics are designed to selectively target and eliminate multidrug-resistant bacteria, including Gram-negative pathogens such as Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, as well as Gram-positive pathogens. Telum's pipeline includes preclinical programs focused on serious infections such as life-threatening bacteremia, nosocomial infections, and those associated with cystic fibrosis.
Target Audience
The primary target audience includes patients suffering from serious multi-drug resistant bacterial infections, as well as healthcare providers and researchers seeking novel antimicrobial therapies.
Features
- APEXp® platform: A proprietary platform using synthetic biology and AI to engineer phage lytic enzymes.
- Engineered Phage Lytic Enzymes (EPLEs): Designed for enhanced antimicrobial activity against multi-resistant bacteria.
- Targeted programs: Focus on treating infections caused by Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterococcus faecium.
- Broad bacteria and phage collection: Sourced from anthropogenic and cave explorations to identify novel lytic enzymes.
- Protein engineering: Optimizes enzybiotics for improved efficacy, stability, and precision.
- High-throughput screening: Identifies and selects leading drug candidates.